Success Metrics

Clinical Success Rate
85.7%

Based on 12 completed trials

Completion Rate
86%(12/14)
Active Trials
2(6%)
Results Posted
25%(3 trials)
Terminated
2(6%)

Phase Distribution

Ph phase_2
3
10%
Ph early_phase_1
1
3%
Ph phase_3
14
45%
Ph not_applicable
2
6%
Ph phase_4
10
32%

Phase Distribution

1

Early Stage

3

Mid Stage

24

Late Stage

Phase Distribution30 total trials
Early Phase 1First-in-human
1(3.3%)
Phase 2Efficacy & side effects
3(10.0%)
Phase 3Large-scale testing
14(46.7%)
Phase 4Post-market surveillance
10(33.3%)
N/ANon-phased studies
2(6.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

12 of 14 finished

Non-Completion Rate

14.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

31

all time

Status Distribution
Active(2)
Completed(12)
Terminated(2)
Other(15)

Detailed Status

unknown15
Completed12
Terminated2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
31
Active
2
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.3%)
Phase 23 (10.0%)
Phase 314 (46.7%)
Phase 410 (33.3%)
N/A2 (6.7%)

Trials by Status

completed1239%
terminated26%
unknown1548%
recruiting26%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT07326540Phase 3

Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

Recruiting
NCT02918409Phase 4

IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy

Completed
NCT05922124Phase 4

Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

Recruiting
NCT06827756Phase 4

Comparative Study of Secondary Prophylaxis for SBP

Completed
NCT05258851Phase 3

Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections

Terminated
NCT05542446Phase 4

Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation

Terminated
NCT05613361Phase 3

The Effect of Curcumin Against Colistin-induced Nephrotoxicity

Unknown
NCT03894046Phase 3

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

Completed
NCT05689229Phase 3

Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial

Completed
NCT05586815Phase 4

Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection

Unknown
NCT05279586Early Phase 1

Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients

Unknown
NCT04995133Phase 4

Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.

Unknown
NCT04208763Not Applicable

A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.

Unknown
NCT04489459Phase 4

Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae

Unknown
NCT04208945Not Applicable

Nebulized Colistin for Gram Negative VAP Prevention.

Unknown
NCT01970371Phase 3

A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)

Completed
NCT03622450Phase 2

The Effect of Colistin Inhalation on Ventilator Associated Pneumonia

Completed
NCT02117986Phase 4

Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients

Unknown
NCT02472600Phase 2

Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy

Unknown
NCT03341741Phase 3

Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients

Completed

Drug Details

Intervention Type
DRUG
Total Trials
31